Targeting the Mitochondrial Genome Through a Nanocarrier and the Regulation of Mitochondrial Gene Expression
Mitochondria are attractive organelles that have the potential to contribute greatly to medical therapy. This organnelle is responsible for a variety of essential functions including ATP production and the regulation of apoptosis, and they have their own genome, mitochondrial DNA (mtDNA). It has recently become evident that a variety of human diseases are associated with mitochondrial dysfunctions caused by mutations and defects in mtDNA. Therefore, the ability to successfully target the mitochondrial genome and to regulate mitochondrial gene expression would contribute to mitochondrial gene therapy for various human diseases. To achieve such an innovative objective, it will be necessary to deliver various cargoes to mitochondria in living cells. However, only a limited number of approaches are available for accomplishing this. In this chapter, we discuss problems associated with mitochondrial delivery systems and mitochondrial gene expression, and propose a strategy for overcoming these problems based our current efforts. To this end, we highlight a MITO-Porter, a mitochondrial delivery system, and show some examples of the regulation of mitochondrial gene expression including mitochondrial RNA knockdown and mitochondrial transgene expression.
KeywordsMitochondria Mitochondrial drug delivery MITO-Porter Mitochondrial genome RNA knockdown Transgene expression Mitochondrial gene therapy
This work was supported, in part, by the Scientific Research (B) from the Ministry of Education, Culture, Sports, Science and Technology of Japanese Government (MEXT). We also thank Dr. Milton Feather for his helpful advice in writing the manuscript.
- Furukawa R, Yamada Y, Kawamura E, Harashima H (2015) Mitochondrial delivery of antisense RNA by MITO-porter results in mitochondrial RNA knockdown, and has a functional impact on mitochondria. Biomaterials 57:107–115. https://doi.org/10.1016/j.biomaterials.2015.04.022 CrossRefPubMedGoogle Scholar
- Sato Y, Sakurai Y, Kajimoto K, Nakamura T, Yamada Y, Akita H, Harashima H (2017) Innovative technologies in nanomedicines: from passive targeting to active targeting/from controlled pharmacokinetics to controlled intracellular pharmacokinetics. Macromol Biosci 17(1). https://doi.org/10.1002/mabi.201600179
- Yamada Y, Akita H, Kamiya H, Kogure K, Yamamoto T, Shinohara Y, Yamashita K, Kobayashi H, Kikuchi H, Harashima H (2008) MITO-porter: a liposome-based carrier system for delivery of macromolecules into mitochondria via membrane fusion. Biochim Biophys Acta 1778(2):423–432. https://doi.org/10.1016/j.bbamem.2007.11.002 CrossRefPubMedGoogle Scholar
- Yasuzaki Y, Yamada Y, Ishikawa T, Harashima H (2015) Validation of mitochondrial gene delivery in liver and skeletal muscle via hydrodynamic injection using an artificial mitochondrial reporter DNA vector. Mol Pharm 12(12):4311–4320. https://doi.org/10.1021/acs.molpharmaceut.5b00511 CrossRefPubMedGoogle Scholar
- Yu H, Koilkonda RD, Chou TH, Porciatti V, Ozdemir SS, Chiodo V, Boye SL, Boye SE, Hauswirth WW, Lewin AS, Guy J (2012) Gene delivery to mitochondria by targeting modified adenoassociated virus suppresses Leber’s hereditary optic neuropathy in a mouse model. Proc Natl Acad Sci U S A 109(20):E1238–E1247. https://doi.org/10.1073/pnas.1119577109 CrossRefPubMedPubMedCentralGoogle Scholar